Alzheimer disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• APOE 16
• MAPT 2
• APP 1
• NRF2 0
• NLRP3 0
• TREM2 0
• AKT 0
• BDNF 0
• TDP-43 2
• PI3K 0
• BACE1 0
• GLP-1 1
• MAPK 0
• PPAR 0
• AMPK 0
• mTOR 0
• PSEN1 1
• STING 0
• ERK 0
• NMDA 1
• SNCA 0
• TLR4 0
• JNK 0
• SIRT1 0
• CTNNB1 0
• STAT3 0
• TP53 0
• TNF 0
• HDAC 0
• HIF-1 0
• SGLT2 0
• HMGB1 0
• GPX4 0
• IL-1 0
• PCSK9 0
• COX-2 0
• HSP90 1
• C9orf72 0
• DPP-4 0
• PINK1 0
• IL-17 0
• TFEB 0
• IL-6 0
• PD-L1 0
• VEGF 0
• YAP 0
• AQP4 0
• CD33 0
• IGF1R 0
• MMP-9 0
• CCR5 0
• EGFR 0
• FTO 0
• GBA1 0
• GIP 0
• JAK 0
• KEAP1 0
• PARP 0
• PD-1 0
• ACE2 0

24 of 5,551 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIMH · F31

  The role of the default mode network in representing and remembering mental states

  Boston College· Chestnut Hill, United States· US$35,733 awarded in fiscal year 2026· until Oct 2028

• U.S. Department of Veterans Affairs · I01

  SleepSMART for Veterans with Insomnia and Mild Cognitive Impairment: A Randomized Clinical Trial

  Va San Diego Healthcare System· San Diego, United States· until Sept 2031

• U.S. Department of Veterans Affairs · IK2

  Cognitive Risk Profiles Among Aging Veterans: Harnessing Big Data for Precision Medicine

  Va San Diego Healthcare System· San Diego, United States· until Sept 2031

• NIH NIA · R03

  Improve and Validate Amyloid Pathology Visualization and Analysis in Intact Brain Samples

  Massachusetts General Hospital· Boston, United States· US$329,220 awarded in fiscal year 2026· until Sept 2028

• NIH NIA · R01

  Enhanced Mapping of Alzheimer's Disease Risk Loci Using Multimodal RNAseq Data

  Emory University· Atlanta, United States· US$653,912 awarded in fiscal year 2026· until May 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Neuroinflammation and Virus Imaging for Smart Therapeutic Approaches (NEUROVISTA)

  Umea Universitet· Umea, Sweden· EU contribution €236,340· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Interneuron subtype-specific control of hippocampal memory encoding and retrieval (INSPIRE)

  Universitaetsklinikum Freiburg· Freiburg, Germany· EU contribution €202,125· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Warfare and Agricultural Resilience Nexus in the Ancient Mediterranean (6th. BC - 4th c. AD) (WARNex)

  University College Dublin, National University of Ireland, Dublin· Dublin, Ireland· EU contribution €252,729· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Attentional Control and Mapping in Spatial Navigation: Defining Behavioral Fingerprints for Early Alzheimer’s Risk Detection (SPATIALOS)

  Universitat Jaume I de Castellon· Castellon De La Plana, Spain· EU contribution €209,915· until Apr 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  Principles of UFMylation-driven antibacterial defence (UBACT)

  Universite de Geneve· Geneve, Switzerland· EU contribution €1,898,233· until Apr 2032

  The disease is named only in the funder's project summary, not in the title.

10 of 5,135 running projects, newest first. Listed amounts together: US$4.3bn + €321.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Adaptation and Normalization of a Verbal Episodic Memory Test in French Sign Language

  NCT06902753· Poitiers University Hospital· Updated 27 Oct 2026

  “Inclusions suspended during the period between phase 1 (adaptation of the test in French sign Language) and phase 2 (inclusion for the standardization of the test).”Registry text, quoted unchanged. Source

• Terminated

  Presence of Anti-RACH Antibodies and Neurocognitive Disorder in Myasthenic or Alzheimers's Patients.

  NCT06523296· Centre Hospitalier Universitaire de Nice· Updated 23 Oct 2026

  “recruitment challenges”Registry text, quoted unchanged. Source

• Terminated

  Home-based tDCS in Frontotemporal Dementia or Alzheimer's Disease

  NCT05978804· Johns Hopkins University· Updated 21 Oct 2026

  “Lack of funding”Registry text, quoted unchanged. Source

• Withdrawn

  GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

  NCT07677865· West China Hospital· Updated 16 Oct 2026

  “poor accrual and funding issues”Registry text, quoted unchanged. Source

• Suspended

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Updated 21 Sept 2026

  “Administrative”Registry text, quoted unchanged. Source

• Withdrawn

  DECIDE: Dyads and Families

  NCT05139290· Emory University· Updated 18 Sept 2026

  “No participants were enrolled in the clinical trial portion. The community-engaged nature of the project required more time than anticipated, and funding was insufficient to support the implementation of the proposed intervention.”Registry text, quoted unchanged. Source

• Withdrawn

  Implementation of AIP Services for Older Adults With AD

  NCT07361601· Northwestern University· Updated 14 Sept 2026

  “Not a clinical trial so retiring ClinicalTrials.gov record”Registry text, quoted unchanged. Source

• Terminated

  The Ketogenic Diet for Alzheimer's Disease

  NCT04701957· Assistance Publique - Hôpitaux de Paris· Updated 10 Sept 2026

  “lake of inclusions”Registry text, quoted unchanged. Source

• Withdrawn

  REVERSE-Long COVID-19 With Baricitinib Study

  NCT05858515· Vanderbilt University Medical Center· Updated 9 Sept 2026

  “This submission for the pilot study has been withdrawn as the full trial opened under a different NCT number before participants enrolled in the pilot.”Registry text, quoted unchanged. Source

• Terminated

  Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

  NCT05267535· Neurim Pharmaceuticals Ltd.· Updated 9 Sept 2026

  “Treatment with 20 mg piromelatine did not demonstrate efficacy over treatment with placebo based on analysis with the ADAS-Cog 14 subscale and with other cognitive and neuropsychiatric parameters.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

  NCT06937229· Bristol-Myers Squibb· Source

• Tailored Education for Aging and Cognitive Health: A Health Behavior Change Intervention for Midlife Adults at Risk for Alzheimer's Disease and Related Dementias

  NCT07933367· Rhode Island Hospital· Source

• PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

  NCT07169630· National Institute of Mental Health (NIMH)· Source

• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

  NCT05980949· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study

  NCT05574400· University of Michigan· Source

• Veech Ketone Ester to Support Brain Energy in Mild Cognitive Impairment and Early Alzheimer's Disease

  NCT06767124· University of Pennsylvania· Source

• A Study of Treatments for the Prevention of Disease Progression in Individuals at Risk for or With Early Onset Alzheimer’s Disease Caused by a Genetic Mutation

  2024-517187-36-01· Washington University School Of Medicine· Source

• A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)

  NCT07781345· Eisai Limited· Source

• CMN LIFU for Enhanced Amyloid Reduction (CLEART Study)

  NCT07866768· University of California, San Francisco· Source

• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

  NCT07011732· Bristol-Myers Squibb· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 86
• Organoids 36
• Mendelian Randomization Analysis 136
• CRISPR-Cas Systems 24
• Gene Expression Profiling 176
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 17
• Exome Sequencing 7
• Proteomics 229
• Metabolomics 81
• Mass Spectrometry 62
• Flow Cytometry 16
• Immunohistochemistry 74
• Liquid Biopsy 5
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 676
• Magnetic Resonance Imaging 1001
• Machine Learning 253
• Deep Learning 166
• Cohort Studies 536
• Genome-Wide Association Study 216

• Cerebral Amyloid Angiopathy in Alzheimer Disease Continuum: Prevalence and Clinical Relevance in a Biomarker-Defined Memory Clinic Cohort.

  Neurology, Nov 2026

• The prevalence of Lewy body pathology across nine international community-based cohorts.

  Brain, Nov 2026

• Transcriptomic signature of frontotemporal lobar degeneration with TDP-43 type C pathology.

  Brain, Nov 2026

• Reproductive Lifespan and Hormonal Therapy in Relation to Later-Life Neurovascular Health in Community-Dwelling Older Women.

  Neurology, Nov 2026

• CogniPaz, an Ecologically Oriented Gamified mHealth Tool for Detecting Mild Cognitive Impairment: Prospective Cohort Diagnostic Accuracy Study.

  JMIR Mhealth Uhealth, Nov 2026

• Angiotensin II Receptor Blockers and the Risk of Alzheimer's Disease Progression: A Population-Based Cohort Study.

  Basic Clin Pharmacol Toxicol, Nov 2026

• Short-interval variability and test-retest reliability of Alzheimer's disease plasma biomarkers in a clinically heterogenous cohort.

  Alzheimers Res Ther, Oct 2026

• Association Between Plasma N-Terminal Tau, Cognitive Decline, and Neurodegeneration in the ADNI Cohort.

  Neurology, Oct 2026

• A genome-wide association study of cognitive impairment in a Chinese cohort of 1,040 individuals.

  Hum Genet, Oct 2026

• Associations of Antibodies Against Several Infections With Alzheimer Disease Neuropathology: A Prospective Cohort Study Analysis.

  Neurology, Oct 2026

See which targets of this disease your abstract mentions, and go to the people working on them.